Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $7.9900 (-0.25%) ($7.8900 - $8.0900) on Thu. Mar. 21, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.17% (three month average) | RSI | 22 | Latest Price | $7.9900(-0.25%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.3% a day on average for past five trading days. | Weekly Trend | ADMS declines -8.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XOP(13%) OIH(12%) XBI(10%) EWI(9%) IBB(9%) | Factors Impacting ADMS price | ADMS will decline at least -2.585% in a week (0% probabilities). BNDX(-11%) UUP(-9%) GDX(-9%) GLD(-8%) GDXJ(-7%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.585% (StdDev 5.17%) | Hourly BBV | 0 () | Intraday Trend | 0.9% | | | |
|
Resistance Level | $8.99 | 5 Day Moving Average | $7.93(0.76%) | 10 Day Moving Average | $7.81(2.3%) | 20 Day Moving Average | $8.99(-11.12%) | To recent high | -34.2% | To recent low | 6.5% | Market Cap | $226m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |